The objective of future treatment for retinoblastoma in children is to improve eye salvage rates. Dr Jesse Berry (Children’s Hospital Los Angeles, University of Southern California, Keck School of Medicine, CA, USA) talks about the current treatment landscape for this disease.<\/p>\n
The presentation, \u2018Tall dark and uh-oh: an ocular oncology update\u2019 was presented at Hawaiian Eye and Retina<\/a> meeting, 14-20 January 2023.<\/span><\/p>\n
Disclosures: <\/strong>Jesse Berry is a consultant to Immunocore (5\/2019), Castle Biosciences (12\/2020) and Biotissue (5\/2021); has received grant\/research support from National Cancer Institute of the\u00a0National Institute of Health Award Number\u00a0K08CA232344 The Wright Foundation Children\u2019s Oncology Group\/St. Baldrick\u2019s Foundation, Danhakl Family Foundation, The Knights Templar Eye Foundation, Research to Prevent Blindness Medical Student Eye Research Fellowship (Recipient: Shreya Sirivolu, Mentor: Jesse Berry)\u00a0 Hyundai Hope on Wheels\u00a0 Childhood Eye Cancer Trust Children\u2019s Cancer Research Fund, A. Linn Murphree, MD, Chair in Ocular Oncology, The Berle & Lucy Adams Chair in Cancer Research The Larry\u00a0and Celia Moh Foundation The Institute for Families, Inc. and Children’s Hospital Los Angeles; and royalties from Elsevier & Springer Provisional Patent Aqueous humor cell free DNA for diagnostic and Prognostic evaluation of Ophthalmic Disease 62\/654,160 (Berry, Xu, Hicks), DNA methylation signature of Retinoblastoma 63\/375,511 (Berry, Xu, Liang, Li).<\/p>\n
Support<\/strong>: Interview and filming supported by Touch Medical Media. Interview conducted by Lisa Glass.<\/p>\n
Filmed as a highlight of <\/em><\/strong>Hawaiian Eye<\/em><\/strong><\/a><\/p>\n
Access more content on Ocular Oncology<\/a>\u00a0here<\/em><\/strong><\/p>\n